Concepedia

Melinda A. Foulk

MA

Statistics

Publications

5

Citations

152

H-Index

5

Active since

2012

Affiliations

AstraZeneca (United States)(Current)

Melinda A. Foulk is an author at AstraZeneca (United States) specializing in life sciences, novel antibacterial drug discovery, and drug discovery.

Publications per year

2012–2015

5

Publications

5

X-ray Crystal Structures of <i>Escherichia coli</i> RNA Polymerase with Switch Region Binding Inhibitors Enable Rational Design of Squaramides with an Improved Fraction Unbound to Human Plasma Protein

Vadim Molodtsov, Paul Fleming, Charles J. Eyermann et al. · Journal of Medicinal Chemistry · 2015 · 43 citations · Full text

, , +16

Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor

Hui Xiong, Melinda A. Foulk, Lisa Aschenbrenner et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 42 citations

, , +10

Novel Rapidly Diversifiable Antimicrobial RNA Polymerase Switch Region Inhibitors with Confirmed Mode of Action in Haemophilus influenzae

Ed T. Buurman, Melinda A. Foulk, Ning Gao et al. · Journal of Bacteriology · 2012 · 29 citations · Full text

, , +17

A Novel High-Throughput Cell-Based Assay Aimed at Identifying Inhibitors of DNA Metabolism in Bacteria

Jun Fan, Boudewijn L. M. de Jonge, Kathy MacCormack et al. · Antimicrobial Agents and Chemotherapy · 2014 · 22 citations · Full text

, , +17

Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens

David C. McKinney, Gregory S. Basarab, Alexis Cocozaki et al. · ACS Medicinal Chemistry Letters · 2015 · 16 citations · Full text

, , +13

1–5 of 5